NCT06595563
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06595563
Title HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ZEPHIR-02)
Acronym ZEPHIR-02
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD | BEL

Facility Status City State Zip Country Details
Institut Jules Bordet RECRUITING Anderlecht Brussels Capital 1070 Belgium Details
CHU Charleroi - Marie Curie NOT_YET_RECRUITING Charleroi 6042 Belgium Details
UZ Gent NOT_YET_RECRUITING Ghent 9000 Belgium Details
UZ Leuven NOT_YET_RECRUITING Leuven 3000 Belgium Details
CHU Liège NOT_YET_RECRUITING Liège 4000 Belgium Details
AZ Delta NOT_YET_RECRUITING Roeselare 8800 Belgium Details
VUMC Amsterdam NOT_YET_RECRUITING Amsterdam 1081 Netherlands Details
UMC Groeningen NOT_YET_RECRUITING Groningen 9713 Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field